Hematology News and Research

RSS

Hematology, also spelled haematology, is the branch of biology (physiology), pathology, clinical laboratory, internal medicine, and pediatrics that is concerned with the study of blood, the blood-forming organs, and blood diseases. Hematology includes the study of etiology, diagnosis, treatment, prognosis, and prevention of blood diseases.

Individuals who naturally lack CCR5 receptor have resistant to HIV

UCLA AIDS Institute researchers successfully removed CCR5 - a cell receptor to which HIV-1 binds for infection but which the human body does not need - from human cells. Individuals who naturally lack the CCR5 receptor have been found to be essentially resistant to HIV.

26 Feb 2010

Philanthropic organizations fund for cancer research studies

Eight philanthropic organizations and families in the Charlotte region have joined forces to create the "Carolinas Kids Cancer Research Coalition," which is providing funding for the introduction of Phase I and Phase II clinical trials by the Pediatric Hematology and Oncology Center at Levine Children's Hospital (LCH).

25 Feb 2010

Biochemical link between misery and death discovered

In ongoing work to identify how genes interact with social environments to impact human health, UCLA researchers have discovered what they describe as a biochemical link between misery and death. In addition, they found a specific genetic variation in some individuals that seems to disconnect that link, rendering them more biologically resilient in the face of adversity.

25 Feb 2010

Genetic test for autism: Transgenomic licenses exclusive intellectual property from IntegraGen

Transgenomic, Inc. announced today that it has licensed on an exclusive U.S. basis intellectual property from IntegraGen SA that will enable Transgenomic to develop and commercialize a genetic test designed to assess the risk of autism in children who have older siblings diagnosed with an autism spectrum disorder. Under the agreement Transgenomic will develop the test in the Company's CAP-accredited and CLIA-certified laboratory, and anticipates launching the new test in the second quarter of 2010. Financial terms of the agreement were not disclosed.

24 Feb 2010

PointCare Technologies donates rapid PointCare NOW tests to Haitian clinics

PointCare Technologies, pioneer inventor of a portable diagnostic system that enables effective HIV/AIDS monitoring for millions of people in remote areas of developing countries, has donated 4,000 (a month's supply) of its rapid PointCare NOW tests to Haitian clinics to ensure the resumption of critical care to HIV/AIDS patients.

24 Feb 2010

Cancer patients frequently face barriers to accessing oral drugs: Study

A comprehensive study of oral oncolytic (anti-cancer) drug treatments revealed that while their use is increasingly common, cancer patients frequently face barriers to accessing oral drugs compared to those delivered intravenously in oncology practice settings.

19 Feb 2010

FDA approves 53 new cancer indications between July 2005 and end of 2007

The U.S. Food and Drug Administration's Office of Oncology Drug Products approved more than 50 new indications for the use of oncology and hematology drugs and biologics between July 2005, when the office began reviewing marketing applications, and the end of 2007, according to a new agency study.

19 Feb 2010

Novartis' Tasigna capsules granted priority review by FDA for treatment of adult patients with Ph+ CML

Novartis announced today that Tasigna® (nilotinib) 200 mg capsules has been granted priority review by the US Food and Drug Administration for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase.

19 Feb 2010

The Hamner Institutes signs formal Memorandum of Understanding with Oslo Cancer Cluster

The Hamner Institutes at Research Triangle Park has signed a formal Memorandum of Understanding with the Oslo Cancer Cluster in Oslo, Norway, one of the leading cancer clusters in Europe. The goal of the collaboration is to strengthen The Hamner's Global BioScience Gateway for Translational Research and Business Development, which began with partnerships in China.

19 Feb 2010

Six states to study sickle cell disease and thalassemias in national pilot project

Medical researchers are developing a new surveillance system to determine the number of patients diagnosed with a family of inherited blood disorders known as hemoglobinopathies, including sickle cell disease, thalassemias, and hemoglobin E disease.

19 Feb 2010

Incyte announces 2009 financial results and key fourth-quarter accomplishments

Incyte Corporation today reported fourth quarter and full year 2009 financial results, provided an update on key fourth quarter accomplishments and 2010 objectives, and announced its 2010 financial guidance.

18 Feb 2010

Children's Hospital of Philadelphia awarded two grants to research into cellular therapies for blood disorders

The new decade may herald an era of cell therapy -- treating human diseases by delivering highly specific beneficial cells. In the wake of an NIH decision late last year permitting federally funded researchers to use new lines of human embryonic stem cells, the door has opened more widely to stem cell research.

16 Feb 2010

Second-quarter fiscal 2010 results announced by Pharmacyclics

Pharmacyclics, Inc. today reported financial results for its second fiscal quarter ended December 31, 2009.

12 Feb 2010

Additional data from Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease presented

Protalix BioTherapeutics, Inc., announced today that additional data from the Company's pivotal Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease was presented at the Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2010 in Miami, Florida, during an oral session titled, "Novel Enzyme Replacement Therapy for Gaucher Disease: Phase III Pivotal Clinical Trial with Plant Cell Expressed Recombinant Glucocerebrosidase (prGCD) - taliglucerase alfa."

12 Feb 2010

PAREXEL International, Proteome Sciences form biomarker alliance

PAREXEL International Corporation, a leading global biopharmaceutical services provider, and Proteome Sciences plc, a leading provider of protein biomarker discovery, validation, and assay development services, today announced the formation of an alliance focused on enhancing PAREXEL's biomarker capabilities for early phase clinical development. PAREXEL is using Proteome Sciences' PS Biomarker Services™ protein and peptide biomarker capabilities to support biopharmaceutical companies in making earlier assessments of new compounds in development.

From Parexel 11 Feb 2010

LRF's 2009 Mantle Cell Lymphoma Consortium report published

Highlights from the Lymphoma Research Foundation (LRF) 2009 Mantle Cell Lymphoma Consortium (MCLC) Scientific Workshop will be published in the March 2010 issue of Leukemia & Lymphoma. Traditionally accessible to subscribers for period of one year, Leukemia and Lymphoma has agreed to make this report available to the public for one month -- Mantle Cell Lymphoma: Report of the 2009 MCL Consortium Workshop.

10 Feb 2010

Acupuncture: An effective pain management therapy for pediatric patients

Doctors at Rush University Medical Center are offering pediatric patients diagnosed with chronic illnesses acupuncture therapy to help ease the pain and negative side effects like nausea, fatigue, and vomiting caused by chronic health conditions and intensive treatments.

10 Feb 2010

Study validates Transgenomic's COLD-PCR technology for colorectal tumor-associated KRAS mutation detection

Transgenomic, Inc. announced today that it has completed a preliminary study with a leading pharmaceutical company that validates the use of its licensed COLD-PCR technology to detect colorectal tumor-associated KRAS mutations that determine efficacy of recently developed therapies. These were detected in plasma samples in which the mutation levels were too low for detection by standard DNA analysis methodologies such as Sanger sequencing.

9 Feb 2010

Nearly 50% of essential services provided for cancer treatment not reimbursed by Medicare

A comprehensive study of the components of the delivery of modern-day cancer care in community oncology practices revealed that Medicare covers only 56% of the actual costs of administering chemotherapy and providing related infusion room services to seniors with cancer. The remaining costs -- for essential services provided such as treatment planning, care coordination, and follow-up care planning -- are not reimbursed by Medicare, causing many oncology practices to struggle to continue to provide care under the Medicare program.

5 Feb 2010

WORLD Symposium: Protalix Biotherapeutics to present data on taliglucerase alfa Phase III Gaucher disease trial

Protalix Biotherapeutics, Inc. today announced that data from its pivotal Phase III trial of taliglucerase alfa in patients with Gaucher disease will be presented at the Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2010, February 10-12, 2010 in Miami, Florida.

5 Feb 2010

Hematology News and Research

Further Reading

Individuals who naturally lack CCR5 receptor have resistant to HIV

Philanthropic organizations fund for cancer research studies

Biochemical link between misery and death discovered

Genetic test for autism: Transgenomic licenses exclusive intellectual property from IntegraGen

PointCare Technologies donates rapid PointCare NOW tests to Haitian clinics

Cancer patients frequently face barriers to accessing oral drugs: Study

FDA approves 53 new cancer indications between July 2005 and end of 2007

Novartis' Tasigna capsules granted priority review by FDA for treatment of adult patients with Ph+ CML

The Hamner Institutes signs formal Memorandum of Understanding with Oslo Cancer Cluster

Six states to study sickle cell disease and thalassemias in national pilot project

Incyte announces 2009 financial results and key fourth-quarter accomplishments

Children's Hospital of Philadelphia awarded two grants to research into cellular therapies for blood disorders

Second-quarter fiscal 2010 results announced by Pharmacyclics

Additional data from Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease presented

PAREXEL International, Proteome Sciences form biomarker alliance

LRF's 2009 Mantle Cell Lymphoma Consortium report published

Acupuncture: An effective pain management therapy for pediatric patients

Study validates Transgenomic's COLD-PCR technology for colorectal tumor-associated KRAS mutation detection

Nearly 50% of essential services provided for cancer treatment not reimbursed by Medicare

WORLD Symposium: Protalix Biotherapeutics to present data on taliglucerase alfa Phase III Gaucher disease trial

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News